Search Articles
Filter Articles
Sections
- All (3,093 articles)
- Pharma Events (45 articles)
- For Recruiters (234 articles)
- Careers Events (5 articles)
- Partners (3 articles)
- News (2,572 articles)
- Careers Advice (262 articles)
- Company Focus (118 articles)
- Company Career Hubs (1 article)
- Pharma Training (6 articles)
- 25 Years of PharmiWeb (13 articles)
- DE&I (1 article)
Found 3,093 articles
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®*, its Third Approved Biosimilar in the U.S.
- 16 Apr 2024
Fresenius, via its operating company Fresenius Kabi, announced today the immediate U.S. availability of Tyenne® (tocilizumab-aazg), a biosimilar of Actemra®** (tocilizumab). Tyenne®, for use in the treatment of chronic autoimmune diseases, is available in an intravenous (IV) formulation.
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
- 16 Apr 2024
Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx (Pixclara™2, 18F-floretyrosine or 18F-FET).
Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw
- 16 Apr 2024
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of the nation's first test for glial fibrillary acidic protein (GFAP), a critical blood-based biomarker for the early detection of neurodegenerative diseases and neurological injuries.
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
- 11 Apr 2024
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
- 11 Apr 2024
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Elecsys pTau217 assay received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
-
Labcorp Receives FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit
- 11 Apr 2024
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Mpox PCR Test Home Collection Kit to aid in the diagnosis of infection with non-variola Orthopoxvirus, including the monkeypox virus that causes monkeypox, also known as mpox.
About Gubra
- 11 Apr 2024
Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases.
About Modus
- 11 Apr 2024
Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis, endotoxemia, severe malaria and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney disease.
About AdrenoMed AG
- 11 Apr 2024
AdrenoMed AG is a German privately financed, clinical-stage biopharmaceutical company.
About PolTREG
- 11 Apr 2024
PolTREG is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs).
About TILT Biotherapeutics
- 11 Apr 2024
TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules including cytokines that can activate T cells and destroy cancer cells.
About Ariceum Therapeutics
- 11 Apr 2024
Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers.
About Alterome Therapeutics, Inc.
- 11 Apr 2024
Alterome Therapeutics, Inc. is a precision oncology biotech developing alteration-specific therapeutics to address high-value and validated oncogenic drivers.
About Viking Therapeutics
- 11 Apr 2024
Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials.
A Recruiter’s Guide to Hiring a Biostatistician
- 11 Apr 2024
In this recruiter guide, we explore the essential considerations for you to keep in mind when hiring a Biostatistician. From understanding the unique demands of the role to identifying key competencies and conducting effective interviews, this guide will help you to focus your candidate search and engage your target audience of talent.
Clinical Research Employers in Europe
- 11 Apr 2024
An up to date list of Employers in Europe, hiring for clinical research positions right now.
About Endo
- 10 Apr 2024
Endo (OTC: ENDPQ) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies.
The Evolution of Clinical Data Management
- 10 Apr 2024
Clinical Data Management (CDM) has drastically transformed over the years, proactively adapting to technological advancements, changing regulations, and the growing complexity of clinical trials.
Eli Lilly's and AstraZeneca's former head of research Dr. Jan Lundberg invests in AlzeCure and is proposed for election to its board
- 10 Apr 2024
AlzeCure Pharma AB (”AlzeCure” or ”the Company”), a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's disease and pain, today announced that Professor Jan Lundberg invests in the company and is proposed as a new member of the company's board of directors.
Cambridge Cognition strengthens senior management team to deliver growth
- 10 Apr 2024
Cambridge Cognition, a leader in digital health solutions for brain health assessment, has announced the appointments of Alex Livingstone-Learmonth as Chief Commercial Officer and Annabelle Miles as Head of Marketing.
